Limits...
Randomized Polypill crossover trial in people aged 50 and over.

Wald DS, Morris JK, Wald NJ - PLoS ONE (2012)

Bottom Line: The results were almost identical to those predicted; 18.4 mmHg, 9.7 mmHg, and 1.4 mmol/L respectively.The Polypill resulted in the predicted reductions in blood pressure and LDL cholesterol.Long term reductions of this magnitude would have a substantial effect in preventing heart attacks and strokes.

View Article: PubMed Central - PubMed

Affiliation: Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

ABSTRACT

Background: A Polypill is proposed for the primary prevention of cardiovascular disease in people judged to be at risk on account of their age alone. Its efficacy in reducing cholesterol and blood pressure is uncertain.

Methods: We conducted a randomized double-blind placebo-controlled crossover trial of a Polypill among individuals aged 50+ without a history of cardiovascular disease and compared the reductions with those predicted from published estimates of the effects of the individual drugs. Participants took the Polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg and simvastatin 40 mg) each evening for 12 weeks and a placebo each evening for 12 weeks in random sequence. The mean within-person differences in blood pressure and low density lipoprotein (LDL) cholesterol at the end of each 12 week period were determined.

Results: 84 out of 86 participants completed both treatment periods. The mean systolic blood pressure was reduced by 17.9 mmHg (95% CI, 15.7-20.1) on the Polypill, diastolic blood pressure by 9.8 mmHg (8.1-11.5), and LDL cholesterol by 1.4 mmol/L (1.2-1.6), reductions of 12%, 11%, and 39% respectively. The results were almost identical to those predicted; 18.4 mmHg, 9.7 mmHg, and 1.4 mmol/L respectively.

Conclusion: The Polypill resulted in the predicted reductions in blood pressure and LDL cholesterol. Long term reductions of this magnitude would have a substantial effect in preventing heart attacks and strokes.

Trial registration: Controlled-Trials.com ISRCTN36672232.

Show MeSH

Related in: MedlinePlus

Flow chart of crossover trial.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3399742&req=5

pone-0041297-g001: Flow chart of crossover trial.

Mentions: Figure 1 is a flow chart of the trial. Trial participants took the Polypill (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) for 12 weeks, and an identical placebo for 12 weeks, the sequence being allocated at random. Neither the participants nor the investigators knew the sequence (ie. “double-blind”). Study treatment was taken once a day in the evening because of the greater efficacy of simvastatin when taken in the evening than in the morning. Existing blood pressure and cholesterol lowering treatments were discontinued at randomisation and no participant received additional blood pressure or cholesterol lowering treatment during the study. The randomization sequence was generated in advance by a computer random number generator, in blocks of 4. Date of birth, height, weight, and sex were recorded at randomization.


Randomized Polypill crossover trial in people aged 50 and over.

Wald DS, Morris JK, Wald NJ - PLoS ONE (2012)

Flow chart of crossover trial.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3399742&req=5

pone-0041297-g001: Flow chart of crossover trial.
Mentions: Figure 1 is a flow chart of the trial. Trial participants took the Polypill (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) for 12 weeks, and an identical placebo for 12 weeks, the sequence being allocated at random. Neither the participants nor the investigators knew the sequence (ie. “double-blind”). Study treatment was taken once a day in the evening because of the greater efficacy of simvastatin when taken in the evening than in the morning. Existing blood pressure and cholesterol lowering treatments were discontinued at randomisation and no participant received additional blood pressure or cholesterol lowering treatment during the study. The randomization sequence was generated in advance by a computer random number generator, in blocks of 4. Date of birth, height, weight, and sex were recorded at randomization.

Bottom Line: The results were almost identical to those predicted; 18.4 mmHg, 9.7 mmHg, and 1.4 mmol/L respectively.The Polypill resulted in the predicted reductions in blood pressure and LDL cholesterol.Long term reductions of this magnitude would have a substantial effect in preventing heart attacks and strokes.

View Article: PubMed Central - PubMed

Affiliation: Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

ABSTRACT

Background: A Polypill is proposed for the primary prevention of cardiovascular disease in people judged to be at risk on account of their age alone. Its efficacy in reducing cholesterol and blood pressure is uncertain.

Methods: We conducted a randomized double-blind placebo-controlled crossover trial of a Polypill among individuals aged 50+ without a history of cardiovascular disease and compared the reductions with those predicted from published estimates of the effects of the individual drugs. Participants took the Polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg and simvastatin 40 mg) each evening for 12 weeks and a placebo each evening for 12 weeks in random sequence. The mean within-person differences in blood pressure and low density lipoprotein (LDL) cholesterol at the end of each 12 week period were determined.

Results: 84 out of 86 participants completed both treatment periods. The mean systolic blood pressure was reduced by 17.9 mmHg (95% CI, 15.7-20.1) on the Polypill, diastolic blood pressure by 9.8 mmHg (8.1-11.5), and LDL cholesterol by 1.4 mmol/L (1.2-1.6), reductions of 12%, 11%, and 39% respectively. The results were almost identical to those predicted; 18.4 mmHg, 9.7 mmHg, and 1.4 mmol/L respectively.

Conclusion: The Polypill resulted in the predicted reductions in blood pressure and LDL cholesterol. Long term reductions of this magnitude would have a substantial effect in preventing heart attacks and strokes.

Trial registration: Controlled-Trials.com ISRCTN36672232.

Show MeSH
Related in: MedlinePlus